Leaflet LAMIVUDINA/TENOFOVIR DISOPROXIL CIPLA 300mg / 245mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: lamivudine + tenofovir disoproxil (nucleoside/nucleotide reverse transcriptase inhibitor + antiretroviral)
ATC: J05AR12 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
This medicine may affect the kidneys.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
The combination of lamivudine and tenofovir disoproxil is used for the treatment of HIV-1 infection and chronic hepatitis B. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.
The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, diarrhea, fatigue, or headaches. In rare cases, lactic acidosis, renal failure, or severe allergic reactions may occur.
This combination is not recommended for patients with severe renal impairment or hypersensitivity to any of the components.
General data about LAMIVUDINA/TENOFOVIR DISOPROXIL CIPLA 300mg / 245mg
- Substance: lamivudine + tenofovir disoproxil
- Date of latest medicines list: 01-12-2020
- Product code: W67140001
- Concentration: 300mg / 245mg
- Pharmaceutical form: film-coated tablets
- Quantity: 30
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.